Regeneron

EYLEA

Manufacturer:

Regeneron

Eylea HCPCS:

J0178

HCPCS Code Descriptor:

Injection, aflibercept, 1 mg

Category:

J Code

Eylea NDCs:

61755-0005-01, 61755-0005-02

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Eylea:

EYLEA is an Opthalmic drug manufactured by Regeneron and administered via the Intraocular route of administration. The J Code: J0178 is aligned to the drug EYLEA.

EYLEA is a vascular endothelial growth factor (VEGF) inhibitor most commonly indicated for patients with Neovascular (Wet) age-Related Macular Degeneration, Macular Edema that occurs after a retinal occlusion, Diabetic Macular Edema, Diabatic Retinopathy, or Retinopathy of Prematurity. VEGFs bind to VEGF receptors (VEGFRs) on a cell’s surface. EYLEA mimics a VEGFR and binds available VEGF-A and placental growth factor (PIGF), members of the VEGF family. This prevents nearby VEGFRs from binding any more VEGF, which may prevent neovascularization in patients with the above diseases. EYLEA is often used in patients over the age of 65. Patient assistance for this medication can be found through EYLEA.

ACCESS PRICING AND MORE BY REGISTERING

J0178 Added Date:

January 1, 2013

J0178 Effective Date:

January 1, 2013

J0178 Termination Date:

HCPCS Active

Eylea billing and coding information can be found through Regeneron at the link below:
Eylea patient assistance information can be found through Eylea Patient Support at the URL: https://eylea.us/s/patient-support
EYLEA prescribing information can be found at the link below:
Information regarding EYLEA’s side effects can be found at MedlinePlus